WuXi Biologics performing CMC work for EpimAb's EMB-01

WuXi Biologics Inc. (HKSE:2269) agreed to provide chemistry, manufacturing and control (CMC) services for the development of preclinical oncology candidate EMB-01 from EpimAb Biotherapeutics Inc. (Shanghai, China). WuXi is responsible for the program’s CMC portion up to IND filing, which the partners expect in mid-2018. EpimAb declined to disclose financial terms, and WuXi did not respond to inquiries.

EpimAb said the product has demonstrated activity in animal models of non-small cell lung cancer (NSCLC). ...